State Street’s GT Biopharma GTBP Stock Holding History

State Street’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-107	Closed	-$20.4K	–	4383
2023 Q4	$20.4K	Hold	107	–	–	﹤0.01%	4341
2023 Q3	$19.3K	Hold	107	–	–	﹤0.01%	4446
2023 Q2	$25K	Sell	107 -2	-2%	-$518	﹤0.01%	4564
2023 Q1	$45K	Hold	109	–	–	﹤0.01%	4526
2022 Q4	$73.2K	Sell	109 -28	-20%	-$35K	﹤0.01%	4460
2022 Q3	$181K	Buy	137 +12	+10%	+$22.9K	﹤0.01%	4196
2022 Q2	$281K	Sell	125 -517	-81%	-$980K	﹤0.01%	4063
2022 Q1	$1.39M	Sell	642 -56	-8%	-$123K	﹤0.01%	3702
2021 Q4	$1.6M	Buy	698 +73	+12%	+$273K	﹤0.01%	3702
2021 Q3	$3.16M	Buy	625 +125	+25%	+$941K	﹤0.01%	3471
2021 Q2	$5.81M	Buy	+500	New	+$5.19M	﹤0.01%	3180

Other funds holding GTBP

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

State Street's GTBP Position: Q1 2024 in Review

State Street sold out of GT Biopharma (GTBP) in Q1 2024, closing a stake of 107 shares — an estimated $20.4K sold.

State Street first reported a position in GTBP in Q2 2021 and held it in 11 quarters. The position peaked at $5.81M in Q2 2021. 11 funds tracked by Wall St. Rank hold GTBP as of Q1 2024.

State Street reported no remaining GT Biopharma position as of Q1 2024 after selling out during the quarter.
State Street sold 107 GT Biopharma shares in Q1 2024, an estimated $20.4K.
State Street first reported a position in GT Biopharma in Q2 2021 and held it in 11 quarters.
State Street's GT Biopharma position peaked at $5.81M in Q2 2021.
11 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2024.

Based on State Street's 13F filing for Q1 2024, filed 15 May 2024.